Clinical development of metabolic inhibitors for oncology

Area of Science:

• Oncology
• Metabolic Pathways
• Cancer Therapeutics

Background:

• Metabolic inhibitors have a long history in cancer treatment, with renewed interest in targeting tumor-specific metabolic alterations.
• Recent research highlights the impact of these inhibitors on the tumor microenvironment (TME), including its acidic, hypoxic, and immunosuppressive nature.
• Non-tumor cells within the TME, such as immune cells, are also affected by metabolic targeting drugs.

Purpose of the Study:

• To review small-molecule metabolic inhibitors currently in clinical development for oncology.
• To evaluate preclinical data on antitumor and TME effects of these agents.
• To provide an overview of the clinical trial landscape for metabolic inhibitors in cancer.

Main Methods:

• Literature review of preclinical studies on metabolic inhibitors.
• Analysis of ongoing clinical trials for metabolic inhibitors in oncology.
• Evaluation of the impact of metabolic inhibitors on tumor cells and the TME.

Main Results:

• Small-molecule metabolic inhibitors are progressing through clinical development for various cancer applications.
• Preclinical studies demonstrate significant antitumor activity and modulation of the TME by these agents.
• Ongoing clinical trials are investigating the efficacy and safety of these metabolic inhibitors in cancer patients.

Conclusions:

• Metabolic inhibitors represent a growing class of cancer therapeutics with potential to target both tumor cells and the TME.
• Further clinical investigation is warranted to establish the role of these agents in improving patient outcomes.
• Targeting tumor metabolism offers a promising strategy for overcoming treatment resistance and enhancing immunotherapy in oncology.